DELFI: DELFI Diagnostics introduces new fragmentomebased cancer treatment monitoring assay
DELFI Diagnostics, Inc., a developer of accessible blood─based tests that deliver a new way to enhance cancer detection, announced availability of the company's fragmentome─based research use only (RUO) cancer
Read full article »
Delfi is a Maryland-based biotechnology company that research and develops fluid biopsy tests for the early detection of cancer.
Read more